natgillin/translations-raw huggingface dataset:
ob upoštevanju predloga sklepa Sveta o sprejetju protokola o spremembi sporazuma o trgovinskih vidikih pravic intelektualne lastnine (TRIPS), sestavljenega 6. decembra 2005 v Ženevi, v imenu Evropske skupnosti (KOM(2006) 175 končno)4 Še neobjavljeno v UL. ,
having regard to the proposal for a Council decision accepting, on behalf of the European Community, the Protocol amending the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), done at Geneva on 6 December 2005 (COM(2006)175) Not yet published in OJ. ,
ob upoštevanju Uredbe št. 816/20065 UL L 157, 9.6.2007, str.
having regard to Regulation No 816/2006 OJ L 157, 9.06.2007. p.
ob upoštevanju sporazuma o trgovinskih vidikih pravic intelektualne lastnine (v nadaljevanju: sporazum TRIPS), sprejetega aprila 1994,
having regard to the Agreement on Trade-Related Aspects of Intellectual Property Rights (hereinafter 'TRIPS Agreement') adopted in April 1994,
ob upoštevanju deklaracije iz Dohe o sporazumu TRIPS in javnem zdravju, ki jo je ministrska konferenca Svetovne trgovinske organizacije (STO) sprejela 14. novembra (v nadaljevanju: deklaracija iz Dohe)6 WT/MIN(01)/DEC/W/2, 14. november 2001. ,
having regard to the Doha Declaration on the TRIPS Agreement and Public Health adopted on 14 November by the Ministerial Conference of the World Trade Organisation (WTO) (hereinafter 'Doha Declaration') WT/MIN(01)/DEC/W/2, 14 November 2001. ,
ob upoštevanju sklepa generalnega sveta STO z dne 30. avgusta 2003 (v nadaljevanju: „sklep STO“), sprejetega v skladu z odstavkom 6 deklaracije iz Dohe o sporazumu TRIPS in javnem zdravju,
having regard to the Decision of the General Council of the WTO of 30 August 2003 (hereinafter 'WTO Decision') adopted pursuant to paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health,
ob upoštevanju protokola o spremembi sporazuma o trgovinskih vidikih pravic intelektualne lastnine (TRIPS), sestavljenega v Ženevi dne 6. decembra 2005 (v nadaljevanju: Protokol),
having regard to the Protocol amending the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), done at Geneva on 6 December 2005 (hereinafter 'Protocol'),
ker je pred začetkom veljave sporazuma TRIPS leta 1994 zmožnost držav v razvoju s srednje visokim prihodkom za proizvodnjo poceni generičnih zdravil narasla, in so tudi zelo revne države začele postajati zmožne pridobivati nekatera poceni generična zdravila na svetovnem trgu, ne glede na to, ali so bili ti proizvodi zaščiteni s patentom ali ne,
whereas before the entry into force in 1994 of the TRIPS Agreement the ability of some middle-income developing countries to produce low-cost generic medicines increased, and even very poor states started to become able to obtain certain low-cost generic medicines on the world market, whether such products were on or off patents,
ker je deklaracija iz Dohe ponovno potrdila tako imenovane prožnosti, vgrajene v sporazum TRIPS, ter jih še razširila z vzpostavitvijo pravnih mehanizmov, s katerimi države, ki nimajo zmogljivosti za proizvodnjo generičnih nadomestkov za draga patentirana zdravila v okviru doma izdanih prisilnih licenc, uvažajo zdravila iz držav, ki so jim zmožne in pripravljene pomagati, brez vmešavanja teh imetnikov patentov,
whereas the Doha Declaration reconfirmed the so-called flexibilities built into the TRIPS Agreement and amplified them further by establishing legal machinery to enable countries lacking the capacity to manufacture generic substitutes for costly patented medicines under domestically issued compulsory licenses to obtain imports from countries able and willing to assist them without interference from the relevant patent holders,
ker bi ta rešitev, ki je na začetku imela obliko opustitve, znane kot „sklep STO“, postala stalna v obliki protokola k sporazumu TRIPS, o katerega sprejetju trenutno razpravlja Evropski parlament,
whereas this solution, initially embodied in a waiver known as the WTO Decision, could be rendered permanent in the form of a Protocol to the TRIPS Agreement whose acceptance is currently under consideration by the European Parliament,
ker člen 30 sporazuma TRIPS članicam dovoljuje, da lahko „določijo omejene izjeme pri izključnih pravicah, ki jih vsebuje patent, če take izjeme niso v nerazumnem nasprotju z običajnim izkoriščanjem patenta in nerazumno ne ogrožajo legitimnih interesov lastnika patenta ob upoštevanju legitimnih interesov tretjih strank“; ker če država, ki daje pomoč, izvaža potrebna zdravila v državo uvoznico, to ne sme pomembno vplivati na lokalni trg države izvoznice;
whereas Article 30 of the TRIPS Agreement allows members to 'provide limited exceptions to the exclusive rights conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties'; whereas, because the assisting country would export needed medicines to the importing country, there should be no significant economic impact on the local market of the exporting country,
ker doslej še nobena država ni uradno obvestila Sveta za sporazum TRIPS, da namerava uporabiti mehanizem, vzpostavljen na podlagi sklepa STO o uvozu cenejših zdravil,
whereas no country has so far made the general notification to the Council for TRIPS of intent to use the mechanism created by the WTO Decision to import cheaper medicines,
ker postopkovne in vsebinske zahteve, ki veljajo za izdajo prisilnih licenc s strani držav uvoznic (če je to potrebno) in izvoznic, kot tudi pogojev in obvestil, povezanih z izdajanjem dovoljenj, predstavljajo najpomembnejše potencialne ovire za učinkovito uporabo sklepa STO,
whereas the procedural and substantive requirements that govern the issuance of compulsory licences by importing (where applicable) and exporting countries, as well as the conditions and notifications connected with that licensing, constitute the principal potential obstacles to effective use of the WTO Decision,
ker je bil protokol posredovan vsem članicam STO, ki ga lahko sprejmejo do 1. decembra 2007 ali do poznejšega datuma, če tako določi ministrska konferenca; ker bo Protokol začel veljati, ko ga bosta sprejeli dve tretjini članic STO,
whereas the Protocol has been submitted to all WTO members and is open for acceptance until 1 December 2007 or such later date as may be decided by the Ministerial Conference; whereas the Protocol will enter into force upon acceptance by two-thirds of WTO members,
ker je doslej stalno spremembo sporazuma TRIPS odobrilo le sedem držav (od 150 članic STO), kar predstavlja 4,7 % vseh članic: Združene države Amerike, Švica, Salvador, Republika Koreja, Norveška, Indija in Filipini,
whereas, to date, only seven countries (out of the 150 WTO members), or 4.7% of the membership, have accepted the permanent amendment of the TRIPS Agreement: the United States, Switzerland, El Salvador, the Republic of Korea, Norway, India and the Philippines,
ker je Evropska unija že prenesla sklep STO v nacionalno pravo in zato odlaganje sprejetja protokola na čas po 1. decembru 2007 ne bi ustvarilo pravne praznine, ampak bi omogočilo dovolj časa za oceno učinkovitosti predlaganega mehanizma in odločitev, ali naj postane stalen,
whereas the European Union has already transposed the WTO Decision into internal law, and consequently delaying acceptance of the Protocol until after 1 December 2007 would not create a legal vacuum, but could allow time to assess the effectiveness of the proposed mechanism in order to decide whether it should be made permanent,
ker bi morala Evropska unija izrecno podpreti polno izvajanje prožnosti iz sporazuma TRIPS v državah v razvoju, ki jih priznava deklaracija iz Dohe, zaradi spodbujanja dostopa do zdravil za vse,
whereas the European Union should expressly endorse full implementation in the developing countries of the flexibilities in the TRIPS Agreement as recognised in the Doha Declaration 'to promote access to medicines for all',
ker je v izvedbeni uredbi o sklepu STO posvečene le malo pozornosti vprašanjem prenosa tehnologije in vzpostavljanju zmogljivosti, saj v uvodni izjavi 13 le razlaga splošni besednjak iz sklepa STO,
whereas the implementing Regulation for the WTO Decision pays scant attention to issues of technology transfer and capacity-building, merely paraphrasing at recital 13 some general language of the WTO Decision,
ker bi se morala Evropska unija vzdržati nalaganja novih obveznosti glede intelektualne lastnine državam AKP in drugim revnim državam v razvoju ter najmanj razvitim državam, ki bi lahko vplivale na njihove programe javnega zdravja,
whereas the European Union should refrain from imposing any new intellectual property obligations on ACP and other poor developing countries and LDCs that could affect their public health programmes,
ker se EU v predlaganih sporazumih o gospodarskem partnerstvu z afriškimi, karibskimi in pacifiškimi državami (AKP) pogaja glede upoštevanja ali sprejetja obveznosti pogodbe o sodelovanju na področju patentov in pogodbe o patentnem pravu;
whereas, in its proposed Economic Partnership Agreements (EPAs) with the African, Caribbean and Pacific (ACP) countries, the EU is negotiating for adherence to or acceptance of the obligations of the Patent Cooperation Treaty (PCT) and the Patent Law Treaty (PLT),
poudarja, da je dostop do farmacevtskih izdelkov po sprejemljivih cenah v revnih državah v razvoju in najmanj razvitih državah bistvenega pomena za doseganje predlaganih razvojnih ciljev Evropske unije in bi prispeval k zmanjšanju revščine, povečanju varnosti ljudi ter spodbujal človekove pravice in trajnostni razvoj;
Stresses that access to affordable pharmaceutical products in poor developing countries and LDCs is essential to attain the proposed EU development goals and would contribute to poverty reduction, increase human security, and promote human rights and sustainable development;
meni, da mora biti cilj politike EU, da se v državah v razvoju kar najbolj poveča razpoložljivost farmacevtskih izdelkov po dostopnih cenah;
Believes that the EU policy should aim at maximising the availability of pharmaceutical products at affordable prices in the developing world;
poziva Svet, naj prizna, da mora Evropska unija nujno sprejeti dodatne ukrepe za spodbujanje prenosa tehnologije, raziskav, krepitve zmogljivosti, regijskih oskrbovalnih sistemov in pomoči pri registraciji, da se olajša in poveča proizvodnja farmacevtskih izdelkov v samih državah v razvoju;
Calls on the Council to recognise that the European Union must take additional measures as a matter of urgency with a view to encouraging the transfer of technology, research, capacity strengthening, regional supply systems and help with registration, in order to facilitate and increase the production of pharmaceutical products by the developing countries themselves;
poziva Komisijo in države članice, da zagotovijo konkretno finančno pomoč za prenos farmacevtske tehnologije v države v razvoju in razvijanje njihovih zmogljivosti na tem področju, kot tudi za lokalno proizvodnjo farmacevtskih izdelkov v vseh državah v razvoju, zlasti v najmanj razvitih državah, pri izpolnjevanju obveznosti iz člena 66(2) sporazuma TRIPS;
Asks the Commission and the Member States to provide concrete financial support for pharmaceutical-related transfer of technology and capacity building for developing countries and local production of pharmaceuticals in all developing countries, especially LDCs, in discharging the obligations established by Article 66(2) of the TRIPS Agreement;
poziva Svet, da sprejme obvezo o določeni ravni financiranja za posodobitev ali izgradnjo zmogljivosti za proizvodnjo farmacevtskih izdelkov v lasti lokalnih oseb v državah v razvoju (vključno z najmanj razvitimi) ter poveča skupno financiranje javno-zasebnega partnerstva pri izvajanju raziskav in razvoju zdravil posebnega pomena za države v razvoju;
Asks the Council to commit to a specified level of funding to upgrade or construct pharmaceutical production facilities owned by local persons in developing (including least developed) countries, and increase the EU aggregate funding to Public-Private Partnerships pursuing research and development of medicines of special relevance to developing countries;
poziva Komisijo, naj v različnih okvirih zagotovi finančna sredstva za raziskave in razvoj na področju bolezni, povezanih z revščino, tropskih bolezni in zapostavljenih bolezni, vključno z javno-zasebnimi partnerstvi in drugimi načini financiranja, obenem pa naj podpira raziskovalne ustanove, ki so pripravljene sodelovati v okviru pobud na področju javnega zdravja, ki si prizadevajo za te cilje;
Asks the Commission to grant funding for R&D on poverty-related, tropical and neglected diseases across a broad spectrum of venues, including Public-Private Partnerships and other possible funding ventures, and to support research institutes willing to cooperate with public health initiatives dedicated to these efforts;
poziva Svet, naj podpre mnenje, da mehanizem, ki je bil vzpostavljen s sklepom STO in protokolom k sporazumu TRIPS, predstavlja v najboljšem primeru le majhen del rešitve problema dostopa do zdravil po sprejemljivih cenah, ter da bodo potrebni drugi ukrepi, če bo hotela Unija prispevati k dejanski in celostni razrešitvi problemov javnega zdravja, s katerim se soočajo države v razvoju;
Asks the Council to support the idea that the mechanism created by the WTO Decision and the Protocol to the TRIPS Agreement represents, at best, only a small part of the solution to the problem of access to medicines at affordable prices and that other measures will be necessary for the European Union to contribute to an effective and comprehensive solution to the public health problems faced in developing countries;
poziva Svet, naj podpira revne države v razvoju, ki uporabljajo tako imenovane prožnosti, vgrajene v sporazum TRIPS in priznane v okviru deklaracije iz Dohe, da bodo v okviru domačih programov javnega zdravja zmožne zagotoviti nujna zdravila po dostopnih cenah;
Asks the Council to support the poor developing countries which use the so-called flexibilities built into the TRIPS Agreement and recognised by the Doha Declaration in order to be able to provide essential medicines at affordable prices under their domestic public health programs;
spodbuja revne države v razvoju, naj uporabijo vsa sredstva, ki jih imajo na razpolago v okviru sporazuma TRIPS, na primer prisilne licence in mehanizem iz člena 30;
Encourages the poor developing countries to use all means available to them under the TRIPS Agreement, such as compulsory licences and the mechanism provided by Article 30;
poziva Svet, naj skupaj s Parlamentom sprejme skupno politično izjavo, da države članice EU lahko še naprej uporabljajo določbo člena 30 o izvzetju sporazuma TRIPS v njihovem domačem patentnem pravu za dovoljevanje proizvodnje in izvoza „z namenom reševanja potreb javnega zdravja in držav uvoznic“ ter poziva Svet, naj Komisijo pooblasti, da se vzdrži sprejemanja ukrepov, ki bi posegali v te postopke;
Calls on the Council to adopt a Joint Policy Statement with Parliament to the effect that EU Member States remain free to use the Article 30 exception provision of the TRIPS Agreement under their domestic patent laws to authorise production and export 'to address public health needs in importing Members', and asks the Council to mandate the Commission to refrain from taking action to interfere with these proceedings;
poziva Svet, naj omeji pooblastilo Komisiji z namenom, da se ta v okviru sporazumov o gospodarskem partnerstvu z državami AKP in drugih prihodnjih dvostranskih in regionalnih sporazumih z državami v razvoju ne bi pogajala o določbah TRIPS-plus, povezanih s farmacevtskimi proizvodi, ki vplivajo na javno zdravje in dostop do zdravil;
Calls on the Council to restrict the mandate given to the Commission so as not to negotiate pharmaceutical-related TRIPS-plus provisions affecting public health and access to medicines in the framework of the negotiation of the Economic Partnership Agreements (EPAs) with the ACP countries and other future bilateral and regional agreements with developing countries:
poziva Komisijo, naj podpre zahtevo, da prijavitelji patentov razkrijejo vir in izvor izuma, ki izhaja iz bioloških virov in je povezan s tradicionalnim znanjem držav v razvoju, da bi se spodbujala pravična delitev koristi in tehnologije, ki izhajata iz teh virov, z državami dobaviteljicami;
Asks the Commission to support disclosure by patent applicants of the source and origin of inventions deriving from biological resources and associated traditional knowledge found in developing countries with a view to promoting the equitable sharing of benefits and technology derived from those resources by supplying countries;
poziva Komisijo, naj podpre „strategije javnih naročil“ iz člena 31(b) in druge strategije, ki bi jih lahko uporabljale države ali skupine držav za zagotavljanje večje kupne moči in ekonomije obsega pri proizvodnji generičnih zdravil po dostopnih cenah in pospeševanje neposredne naložbe v zmogljivosti lokalne proizvodnje v regiji;
Calls on the Commission to support 'pool procurement strategies' under Article 31(b) and other strategies which could be used by countries or groups of countries to provide greater buying power and economies of scale in the production of generic medicines at affordable prices and stimulate direct investment in local production facilities within a region;
poziva Svet, naj Komisijo pooblasti, da proaktivno podpira delo medvladne delovne skupine za javno zdravje, inovacije in intelektualno lastnino pri svetovni zdravstveni organizaciji in poziva Komisijo ter da redno poroča Evropskemu parlamentu o delu te skupine;
Asks the Council to mandate the Commission to proactively support the work of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) at the WHO and to report regularly to Parliament on its work;
spodbuja farmacevtske družbe, naj si prizadevajo za alternativne načine oblikovanja cen, ki naj vključujejo pristop „velika količina, majhna marža“, s pomočjo katerega bi povečali dostop do zdravil, ne da bi se bilo treba zatekati k uporabi prisilnih licenc;
Encourages pharmaceutical companies to pursue pricing alternatives involving a high-volume, low-margin approach, which could enhance access to medicines without the need to invoke compulsory licences;
opozarja, da ponarejanje zdravil kot tako ni povezano s problemom patentov; opozarja, da je treba ukrepe proti ponarejanju sprejeti na področju kazenskega pregona (kazenskih sankcij) in zakonodaje o zdravilih, ne pa s povečanjem ravni zaščite intelektualne lastnine;
Recalls that counterfeiting of medicines is not a patent issue as such; stresses that measures to tackle counterfeiting need to be taken in the area of criminal enforcement (penal sanctions) and drug regulation and not by increasing levels of intellectual property protection;
naroči svojemu predsedniku, naj to resolucijo posreduje Svetu, Komisiji, vladam držav članic EU in držav AKP, STO in vodjem organizacij UNAIDS, UNDP in UNFPA.
Instructs its President to forward this resolution to the Council, the Commission, the governments of the EU Member States and ACP countries, the WTO and the heads of UNAIDS, UNDP and UNFPA.
ob upoštevanju izjave četverice 30. maja 2007,
having regard to the statement of the Quartet of 30 May 2007,
ker se je Hamas odločil, da z vojaškimi sredstvi prevzame oblast v Gazi, in je izpeljal uboje pripadnikov varnostnih sil Fataha in palestinske uprave, kljub temu, da sta palestinski zakonodajni svet in predsedstvo – dve demokratično izvoljeni telesi – nedavno oblikovali vlado narodne enotnosti na podlagi deklaracije iz Meke,
whereas Hamas has decided to take power in Gaza by military means and carried out the killing of Fatah and Palestinian Authority security force members despite the recent formation by the Palestinian Legislative Council and Presidency – both democratically elected bodies – of a unity government on the basis of the Mecca Declaration,
ker je takšen dramatičen razvoj dogodkov predvsem posledica politične nestabilnosti in rastoče delitve na palestinski strani, pa tudi pomanjkanja perspektive za pristen mirovni proces za palestinsko ljudstvo, ki je še vedno žrtev okupacije, ter neuspeha četverice, vključno z EU, da ustrezno prizna demokratičen izid palestinskih volitev,
whereas this dramatic development is due mainly to the political instability and growing division on the Palestinian side, and also to a lack of perspective for a genuine peace process for the Palestinian people still subject to occupation and to the failure of the Quartet, including the EU, properly to acknowledge the democratic results of the Palestinian elections,
ker je po Hamasovem prevzemu nadzora v Gazi predsednik Mahmud Abas imenoval novo začasno vlado, ki jo vodi premier Salam Fajad, in ker je izraelska vlada pripravljena sodelovati in sklepati dogovore s to začasno vlado,
whereas following the takeover of Gaza by Hamas, President Abbas appointed a new emergency government led by Prime Minister Fayyad, and whereas the Israeli Government is open to cooperation and engagement with this emergency government,
ker se humanitarne razmere v Palestini, zlasti v Gazi, ob vedno večji revščini, pomanjkanju osnovnih storitev, zamrznitvi plač številnim državnim uslužbencem in splošnem občutku ponižanja med prebivalstvom, bližajo popolnemu razsulu ter se po nedavnem razvoju dogodkov še naprej slabšajo,
whereas the humanitarian situation in Palestine, and particularly in Gaza, is close to total collapse and is deteriorating further following the recent developments, with widespread poverty, a lack of basic services, a freeze on many civil servants’ salaries and a general sense of humiliation within the population,
ker se je ta položaj zdaj še poslabšal zaradi zaostritve palestinskega notranjega konflikta,
whereas this situation is now aggravated by the escalation of a Palestinian internal conflict,
ker obsoja, da palestinske radikalne skupine izstreljujejo rakete na območje Sderota v Izraelu, ki so nedavno ubile dva civilista, mnoge pa ranile, ter povračilne ukrepe izraelskih sil, zaradi katerih je bilo ubitih več kot 100 Palestincev, po večini civilistov,
condemning both the firing of rockets at the Sderot area in Israel by Palestinian radical groups, which recently killed two civilians and injured many more, and the retaliation by the Israeli forces, which resulted in the killing of more than 100 Palestinians, most of whom were civilians,
ker je četverica v prizadevanju po ponovni potrditvi svoje politične pobude v konfliktu ravnokar imenovala nekdanjega britanskega predsednika vlade Tonya Blaira za novega odposlanca za Bližnji vzhod,
whereas the Quartet has just appointed former British Prime Minister Tony Blair as the new Middle East Envoy in an effort to reaffirm its political initiative in the conflict,
ker obnovitev arabske mirovne pobude na vrhu Arabske lige v Riadu 29. marca 2007 ponuja novo in verodostojno priložnost za celovito pomiritev v tej regiji,
whereas the relaunching of the Arab Peace Initiative at the Riyadh summit of the Arab League of 29 March 2007 offers a new and credible opportunity for a comprehensive settlement in the region,
ker pomanjkanje enotnosti na palestinski strani in vsakodnevne spremembe razmer na terenu zaradi širitve naselbin in gradnje izraelskega zidu nenehno spodbijajo možnost nastanka suverene palestinske države, ki bi bila sposobna preživeti,
whereas the prospect of a viable Palestinian State is being constantly undermined by both the lack of unity on the Palestinian side and the daily change in the situation on the ground, with the expansion of settlements and construction of the Israeli wall,
ker je desetnik izraelske vojske Gilad Šalit še vedno talec radikalnih skupin v Gazi, medtem ko Izrael v zaporih še vedno zadržuje več tisoč Palestincev, tudi članov nekdanje vlade in zakonodajnega sveta,
whereas the Israeli Corporal Shalit is still being held hostage by radical groups in Gaza, while thousands of Palestinians, including members of both the former government and the Legislative Council, are still being held in jail by Israel,